At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
RVL-1201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis
In Brief
A Phase 2 clinical trial evaluating RVL-1201 and RVL-1201 Vehicle Placebo for Blepharoptosis. Completed, enrolled 46 participants across 1 site.
Detailed Summary
This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharoptosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionJan 2014
Study CompletionFeb 2014
TodayJul 2026
First PostedMay 7, 2013
Enrollment StartMay 1, 2013
Primary CompletionJan 1, 2014
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.2 years ago
Interventions
RVL-1201drug
RVL-1201 0.1% Ophthalmic Solution
RVL-1201 Vehicle Placebodrug
RVL-1201 Vehicle Placebo